Scientific publications
Building on the clinical applicability of ctDNA analysis in non-metastatic pancreatic ductal adenocarcinoma. Scientific Publication
Ibone Labiano 1 , Ana E Huerta 1 , Maria Alsina 2 3 , Hugo Arasanz 1 4 , Natalia Castro 1 , Saioa Mendaza 1 , Arturo Lecumberri 1 4 , Iranzu Gonzalez-Borja 1 , David Guerrero-Setas 5 , Ana Patiño-Garcia 6 , Gorka Alkorta-Aranburu 7 , Irene Hernández-Garcia 1 4 , Virginia Arrazubi 1 4 , Elena Mata 1 4 , David Gomez 1 4 , Antonio Viudez 1 , Ruth Vera 1 4
Abstract
Pancreatic ductal adenocarcinoma represents one of the solid tumors showing the worst prognosis worldwide, with a high recurrence rate after adjuvant or neoadjuvant therapy.
Circulating tumor DNA analysis raised as a promising non-invasive tool to characterize tumor genomics and to assess treatment response. In this study, surgical tumor tissue and sequential blood samples were analyzed by next-generation sequencing and were correlated with clinical and pathological characteristics.
Thirty resectable/borderline pancreatic ductal adenocarcinoma patients treated at the Hospital Universitario de Navarra were included. Circulating tumoral DNA sequencing identified pathogenic variants in KRAS and TP53, and in other cancer-associated genes. Pathogenic variants at diagnosis were detected in patients with a poorer outcome, and were correlated with response to neoadjuvant therapy in borderline pancreatic ductal adneocarcinoma patients.
Higher variant allele frequency at diagnosis was associated with worse prognosis, and thesum of variant allele frequency was greater in samples at progression.
Our results build on the potential value of circulating tumor DNA for non-metastatic pancreatic ductal adenocarcinoma patients, by complementing tissue genetic information and as a non-invasive tool for treatment decision. Confirmatory studies are needed to corroborate these findings.
CITATION Sci Rep. 2024 Jul 13;14(1):16203. doi: 10.1038/s41598-024-67235-y
Our authors
